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BACKGROUND: The objectives of this phase I study were to determine the safety, pharmacokinetics (PK), pharmacodynamics and
efficacy of brivanib combined with full-dose cetuximab in patients with advanced gastrointestinal malignancies.
METHODS: Patients with advanced gastrointestinal malignancies who had failed prior therapies received brivanib (320, 600 or 800mg
daily) plus cetuximab (400mgm–2 loading dose then 250mgm–2 weekly). Assessments included adverse events, PK, tumour
response, 2[18F]fluoro-2-deoxyglucose positron-emitting tomography and K-Ras mutation analyses.
RESULTS: Toxicities observed were manageable; the most common treatment-related toxicities (410% of patients) were fatigue,
diarrhoea, anorexia, increase in aspartate aminotransferase and alanine aminotransferase, acneiform dermatitis, headache, mucosal
inflammation, nausea, dry skin, vomiting, hypertension, pruritus, proteinuria and weight loss. Of 62 patients, 6 (9.7%) had objective
radiographic partial responses, with an overall response rate of 10%. Median duration of response was 9.2 months; median
progression-free survival was 3.9 months.
CONCLUSIONS: The acceptable toxicity profile and efficacy of brivanib observed in this study were promising. These findings are being
further evaluated in a phase III study of brivanib plus cetuximab vs cetuximab alone in patients previously treated with combination
chemotherapy for K-Ras wild-type advanced metastatic colorectal cancer.
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Angiogenesis is critical for growth, metastasis and invasion of
tumours (Kerbel, 2008). Vascular endothelial growth factor
(VEGF) is the major mediator of angiogenesis, although multiple
other angiogenic factors such as fibroblast growth factor-1 (FGF-1,
aFGF) and -2 (FGF-2, bFGF) and platelet-derived growth factor are
involved in the initiation and maintenance of angiogenesis and
tumourigenesis (Kerbel, 2008). Bevacizumab, which inhibits VEGF
receptor-2 (VEGFR-2) signalling through inhibition of VEGF-A
ligand binding, prolongs survival in patients with metastatic
colorectal cancer in both the first- and second-line settings when
used in combination with cytotoxic chemotherapy; however,
observed responses are transient, with a median overall survival
of 12.9 months for patients receiving second-line treatment and 23
months for those receiving first-line treatment (Kabbinavar et al,
2003; Hurwitz et al, 2004; Giantonio et al, 2007).
Cetuximab, a chimeric monoclonal antibody targeting the
epidermal growth factor receptor (EGFR), has demonstrated efficacy
and overall survival benefits in patients with K-Ras wild-type
metastatic colorectal cancer (Cunningham et al, 2004; Sobrero et al,
2008). Preclinical studies suggest that VEGF overexpression has a
role in acquired resistance to anti-EGFR therapy (Bianco et al, 2008)
and that dual inhibition of VEGF and EGF signalling may overcome
such resistance (Naumov et al, 2009). It is unclear whether these
observations translate into prolonged clinical benefit.
Upregulation of alternate proangiogenic signals, such as the FGF
signalling pathway, is one of the proposed mechanisms in the
development of resistance to VEGF-directed antiangiogenic
therapy (Bergers and Hanahan, 2008). Serum bFGF levels have
been shown to be increased following first-line treatment of
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patients with metastatic colorectal cancer treated with combina-
tion chemotherapy and monoclonal anti-VEGF antibody therapy
(Kopetz et al, 2009). Targeting FGF, VEGF and EGF signalling
pathways simultaneously may provide additional clinical benefit to
patients with advanced gastrointestinal malignancies. Brivanib is
the first orally bioavailable selective dual inhibitor of FGF and
VEGF signalling and is administered as brivanib alaninate, the
L-alanine ester prodrug of the active moiety brivanib. In preclinical
studies, brivanib has shown strong antiangiogenic and antitumour
effects on tumour cells across a range of tumour types, including
colon, breast, liver and lung (Bhide et al, 2006, 2010; Huynh et al,
2008), and no evidence of evasive resistance when administered to
RIP-Tag2/Bl6 mice (Allen et al, 2009). In a recent phase II study in
advanced/metastatic hepatocellular carcinoma, brivanib demon-
strated encouraging efficacy, with an overall survival of 10 months,
and was generally well tolerated (Park et al, 2011). Cetuximab has
been combined with anti-VEGF monoclonal antibody therapy
(bevacizumab) safely with preliminary suggestion of improved
efficacy (Saltz et al, 2007); however, large, randomised phase III
studies failed to show a survival benefit associated with cetuximab
or panitumumab when added to bevacizumab plus cytotoxic
chemotherapy (Hecht et al, 2009; Tol et al, 2009). The FGF
pathway is a known alternate angiogenesis pathway to the VEGF
pathway and may account for the resistance to anti-VEGF therapy
(Kopetz et al, 2009); thus a combined VEGF and FGF receptor
inhibitor holds the promise of superior efficacy when used in
combination with an EGFR pathway inhibitor.
The primary goals of the current study were to (a) define a dose
for combination treatment with brivanib alaninate and cetuximab
for further evaluation in phase II/III studies, (b) develop knowl-
edge about dose-limiting toxicity (DLT) and (c) assess the
preliminary efficacy and safety of this combination therapy in
patients with advanced gastrointestinal malignancies.
MATERIALS AND METHODS
Patients
Patients were required to have the following characteristics: age
X18 years; Eastern Cooperative Oncology Group performance
status score 0 or 1; histologic or cytologic diagnosis of
gastrointestinal malignancy (if the patient entered during the
dose-expansion phase, they had to have tissue-verified colorectal
cancer); tumour biopsy tissue available for correlative biomarker
analysis (K-Ras testing on tissue was performed post hoc after trial
completion); radiographic or tissue confirmation that the disease
was locally advanced/metastatic; measurable disease; adequate
bone marrow, hepatic and renal function; toxicity related to prior
therapy had to be resolved to baseline or deemed irreversible; at
least 4 weeks had to pass since last chemotherapy, immunother-
apy, radiotherapy, anticancer hormonal therapy or targeted
therapy, and at least 6 weeks since last therapy with bevacizumab,
nitrosoureas, mitomycin C and/or liposomal doxorubicin; and
women of child-bearing age had to have a negative pregnancy test.
Prior anti-EGFR therapy and anti-VEGF monoclonal antibody
therapy were allowed. Patients who had prior treatment with
VEGFR-tyrosine kinase inhibitors were ineligible. A DLT was
defined, for the purposes of this study, as any of the follow-
ing events occurring in the first 4 weeks of study treatment:
grade 4 neutropenia (i.e. absolute neutrophil count (ANC)
o500 cellsmm–3 for 5 or more consecutive days) or febrile
neutropenia (i.e. fever 4381C with an ANC o500 cellsmm–3
requiring hospitalisation); grade 4 thrombocytopenia or bleeding
episode requiring platelet transfusion; grade 3 nausea and/or
emesis despite the use of maximal medical intervention; grade 2 or
greater cardiovascular toxic effect; any grade 3 or greater
nonhaematologic toxic effect; or delayed recovery (2 weeks or
more) after scheduled re-treatment from a delayed toxic effect
related to treatment with cetuximab and brivanib.
Study design
This was an open-label, phase I study of brivanib alaninate
administered orally in combination with intravenous cetuximab to
patients with advanced gastrointestinal malignancy. This study
was conducted in accordance with good clinical practice, as
defined by the International Conference on Harmonization and in
accordance with the ethical principles underlying European Union
Directive 2001/20/EC and the United States Code of Federal
Regulations, Title 21, Part 50 (21CFR50). The protocol, amend-
ments and patient-informed consent received appropriate ap-
proval by the respective Institutional Review Board/Independent
Ethics Committees prior to study initiation. Informed consent was
obtained from each patient prior to study participation.
The primary objective was to assess the DLT of brivanib
alaninate in combination with cetuximab and to define the
maximum tolerated dose (MTD) in patients with advanced
gastrointestinal malignancy who had failed prior therapy.
Secondary objectives included assessment of radiographic
evidence of antitumour activity, evaluation of changes by
2[18F]fluoro-2-deoxyglucose positron-emitting tomography
(FDG-PET) scan and/or radiologic response as defined by the
modified World Health Organisation (WHO) criteria, duration of
response, duration of disease control and time to progression at
doses other than the MTD. Additional FDG-PET-specific objectives
were to assess the tumour metabolic response and the association
of tumour metabolic changes with clinical outcome (progression-
free survival; PFS) in this study population and to assess the
reproducibility of FDG-PET measurements of standardised uptake
value (SUV) parameters in this multicentre trial. Additional
secondary objectives were to determine the disease control rates,
duration of response, duration of disease control and PFS based on
the modified WHO criteria in response-evaluable patients at the
MTD, and to assess the pharmacokinetics (PK) of brivanib
alaninate when administered in combination with cetuximab.
A post hoc additional exploratory biomarker analysis to evaluate
the relationships between K-Ras mutation status and efficacy end
points in patients with colorectal cancer was performed.
Treatment
On cycle 1, day 1 of a 28-day treatment cycle, a single dose of
brivanib alaninate was administered, followed by a 6-day washout
period. On cycle 1, day 8, continuous daily oral dosing of brivanib
alaninate was started together with a single loading dose of
intravenous cetuximab 400mgm–2 infused over 120min. Begin-
ning on cycle 1, day 15, cetuximab was administered weekly at
250mgm–2, infused over 60min. For the remainder of the study,
patients received oral brivanib alaninate on a daily continuous
schedule and intravenous cetuximab on a weekly basis. Dose
escalation of brivanib alaninate starting at 320mg with two
additional escalations of 600 and 800mg was explored (see
Appendix A for further treatment details).
Assessments
Safety Adverse events (AEs) were evaluated according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events (v 3.0) on a continuous basis, while the patient
was on study and until p30 days after the last dose of study drug
or until all treatment-related AEs had recovered to baseline or were
deemed irreversible. Once a subject had been off treatment due to
toxicity, assessments were to be made every 28 days until all study-
related toxicities resolved to baseline, stabilised or were deemed
irreversible.
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Pharmacokinetics Brivanib alaninate is rapidly converted to
brivanib (the active moiety) in vivo. Hence, only the active moiety
was measured in plasma. Plasma samples for determination of
brivanib concentrations were drawn pre-dose and serially (15, 30
and 45min, and 1, 2, 4, 6, 8 and 24 h after dosing) after dosing on
cycle 1, day 1 and cycle 1, day 8. Serum samples for determination
of cetuximab concentrations were drawn pre-dose and serially (2,
4, 6 and 24 h after dosing) after dosing on cycle 1, day 8. Serum
samples for both brivanib and cetuximab were also drawn pre-
dose on cycle 1, day 15 and cycle 2, day 1. For analyses of brivanib
and cetuximab concentrations in serum and plasma samples, see
Appendix B.
Efficacy Tumour response was determined using modified WHO
criteria (see Appendix C).
FDG-PET and K-Ras mutations analyses See Appendix D.
Statistical methods
Cohorts of 3–10 patients were to be treated at each dose level until
the MTD was defined based on observance of DLTs; however, the
MTD was not reached due to lack of DLT. Thus, at the maximum
dose level (MDL) of 800mg, a total of 40 response-evaluable
patients were accrued in two stages, with the number of patients at
each stage based on a modified Gehan two-stage approach (see
Appendix E for further details on statistical analyses).
RESULTS
Patient disposition and demographics
Eighty-five patients were enrolled on this study, 62 of whom were
treated with brivanib alaninate (Table 1) and 61 of whom received
brivanib alaninate plus cetuximab (24 of the 85 patients failed
screening). The majority of patients were males (61% vs 39%);
median age was 60 years. Fifty-nine patients had colorectal cancer,
two had oesophageal cancer and one had fibrolamellar hepatocel-
lular carcinoma. The most common metastatic sites were liver (53
patients), lung (51 patients) and lymph node (19 patients).
Safety
The MTD was not formally reached and the expansion cohort was
opened at the predefined MDL based on the MTD (800mg)
reached in the phase I brivanib monotherapy study (CA182002)
(Jonker et al, 2010). One patient had a DLT (bilateral pulmonary
embolism) considered possibly related to treatment with brivanib
alaninate at a dose of 320mg combined with cetuximab. The event
did not lead to any further complications, but the patient died
3 weeks later due to disease progression. No further DLTs occurred
at any dose.
Overall, brivanib treatment-related AEs were acceptable when
administered daily at doses of 320, 600 and 800mg in combination
with cetuximab (Table 2). Six patients (9.7%), all of whom were in
the 800-mg cohort, had grade 1/2 palmar–plantar dysesthesias.
The majority of treatment-related AEs were grade 1/2 in
severity. The most frequently reported treatment-related grade
3/4 AEs (45% of patients) were fatigue and increase in hepatic
transaminases. The incidence of grade 3/4 palmar–plantar
dysesthesias was infrequent, with only one reported case in the
800-mg cohort (1.6% of patients). In total, 14 patients (22.6%)
reported serious (grade 3/4) treatment-related AEs during the
study, including vomiting, dehydration and pyrexia. Seven patients
discontinued due to study drug-unrelated AEs, including small
intestinal obstruction, vomiting, pneumonia, left ventricular
dysfunction, hyperbilirubinaemia, drug hypersensitivity to cetux-
imab, disease progression, angio-oedema and hypertension in one
patient each. In addition, pneumonia and malignant neoplasm
progression occurred in the same patient. Four patients discon-
tinued due to drug-related toxicities, which included sepsis,
aspartate aminotransferase elevation, dehydration and angio-
oedema. All AEs leading to study discontinuation occurred in
the 800-mg cohort.
Twenty patients had at least one dose reduction, including two
in the 600-mg cohort and 18 in the 800-mg cohort. No patient in
the 320-mg cohort had a dose reduction. Dose reductions due to
cetuximab-related AEs occurred across all cohorts in 16 patients
(26%), two in the 600-mg cohort and 14 in the 800-mg cohort.
Reasons for dose reduction were delayed nonhaematologic
recovery (five patients, 8%), skin toxicity (four patients, 6%) and
delayed haematologic recovery (one patient, 2%).
In all, 15 patients died during the study, 14 due to disease
progression and 1 due to study drug toxicity. One patient, who was
treated with brivanib alaninate 800mg in combination with
cetuximab, died on day 47 due to sepsis related to rectal
perforation. Both events were considered possibly related to
treatment.
Pharmacokinetics
At the MDL, cetuximab had no effect on brivanib maximum
plasma concentration (Cmax) or area under the plasma
Table 1 (a) Baseline demographics and characteristics and (b) prior
therapy
Brivanib alaninate dose, mg
Total
320 (n¼ 6) 600 (n¼ 5) 800 (n¼ 51) (N¼ 62)
(a)
Median age (min, max) 61 (50, 65) 59 (28, 74) 60 (31, 78) 60 (28, 78)
Age, n (%)
r65 years 5 (83) 4 (80) 36 (71) 45 (73)
X65 years 1 (17) 1 (20) 15 (29) 17 (27)
Gender, n (%)
Male 3 (50) 2 (40) 33 (65) 38 (61)
Female 3 (50) 3 (60) 18 (35) 24 (39)
Tumour type
Oesophagus 1 (17) 1 (2) 2 (3)
Colorectal 5 (83) 4 (80) 50 (98) 59 (65)
Othera 0 (0) 1 (20) 0 (0) 1 (2)
(b)
Prior therapy, n (%)
Total
(N¼ 62)
Prior surgery 59 (95)
Prior radiotherapy 20 (32)
Prior hormonal, immunologic or biologic therapy 41 (66)
Prior VEGF-targeted therapy 36 (58)
Bevacizumab 34 (55)
VEGF trap 2 (3)
Prior EGFR-targeted therapy 27 (44)
Cetuximab 21 (34)
Panitumumab 6 (10)
Prior chemotherapy 59 (95)
No. of regimens
1 10 (16)
2 15 (24)
X3 34 (55)
Abbreviations: EGFR¼ epidermal growth factor receptor; VEGF¼ vascular endo-
thelial growth factor. aFibrolamellar liver tumour.
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concentration–time curve extrapolated to infinity (AUC(INF)):
90% CIs for the Cmax and AUC(INF) geometric mean ratios with
and without cetuximab were within the 80–125% interval (Table 3).
Efficacy
Six patients (9.7%) achieved a partial response, all of whom were
in the brivanib alaninate 800mg dose group, resulting in an
objective response rate of 10%. Twenty-eight patients (45%)
achieved stable disease (three in the brivanib alaninate 320mg
dose group, three in the brivanib alaninate 600mg dose group and
22 in the brivanib alaninate 800mg dose group), 15 patients
(24.2%) had disease progression (two in the brivanib alaninate
320mg dose group, two in the brivanib alaninate 600mg dose
group and 11 in the brivanib alaninate 800mg dose group).
Radiographic response was not evaluable in 13 patients (21%). The
median duration of response was 9.2 months (95% CI: 7.20, 16.4
months; n¼ 6), the median duration of disease control was 5.5
months (95% CI: 3.84, 7.32 months; n¼ 28) and the median
duration of stable disease was 5.3 months (95% CI: 3.68, 5.55;
n¼ 21). The median PFS was 3.9 months (95% CI: 3.38, 5.42
months; n¼ 51).
FDG-PET and K-Ras analyses
Results of FGD-PET and K-Ras analyses are reported in Appendix F.
DISCUSSION
This phase I study evaluated the safety, PK, pharmacodynamics
and efficacy of brivanib combined with full-dose cetuximab in
patients with advanced gastrointestinal malignancies. The MTD of
the combination of cetuximab and brivanib was not established at
the prespecified MDL of 800mg, although this dose was
determined to be the MTD for monotherapy in a previous phase
I study (Jonker et al, 2010). One DLT occurred at the 320-mg dose
level in one patient who experienced bilateral pulmonary artery
emboli. The toxicity profile of brivanib alaninate in combination
with cetuximab observed in this study was manageable.
The population in the current study was heavily pretreated,
having advanced-stage disease; the majority of patients had
received three or more previous lines of treatment and B40% of
patients had prior EGFR inhibitor therapy. Despite this, brivanib
alaninate in combination with cetuximab demonstrated promising
antitumour activity, with an objective response rate of 10% at the
MDL and a PFS of 3.9 months. Objective responses were not noted
in the 11 patients treated with low-dose brivanib group, despite
concomitant cetuximab therapy, possibly because of the low
number of patients in this subgroup and the inclusion of patients
with gastrointestinal malignancies other than colorectal cancer
(where cetuximab does not have a proven efficacy as mono-
Table 2 Most common treatment-related (investigator determined) AEs and serious AEs
Brivanib alaninate dose, mg Total
(N¼ 62) Total (N¼ 62)
AE
320mg
(n¼ 6), n (%)
600mg
(n¼ 5), n (%)
800mg
(n¼ 51), n (%)
415% incidence,
any grade, n (%)
worst CTC grade,
grade 3/4, n (%)
Any AE 6 (100.0) 5 (100.0) 43 (84.3) 54 (87.1) 27 (43.5)
Dermatitis 1 (16.7) 1 (20.0) 14 (27.5) 16 (25.8) 2 (3.2)
Fatigue 3 (50.0) 2 (40.0) 30 (58.8) 25 (56.5) 8 (12.9)
Diarrhoea 1 (16.7) 2 (40.0) 18 (35.3) 21 (33.9) 1 (1.6)
Anorexia 1 (16.7) 1 (20.0) 19 (37.3) 21 (33.9) 2 (3.2)
AST increased 0 1 (20.0) 19 (37.3) 20 (32.3) 5 (8.1)
ALT increased 1 (16.7) 1 (20.0) 16 (31.4) 18 (29.0) 6 (9.7)
Vomiting 1 (16.7) 1 (20.0) 8 (15.7) 10 (16.1) 2 (3.2)
Headache 0 1 (20.0) 13 (25.5) 14 (22.6) 0 (0)
Mucositis 0 0 12 (23.5) 12 (19.4) 0 (0)
Nausea 1 (16.7) 1 (20.0) 10 (19.6) 12 (19.4) 1 (1.6)
Xerodermatitis 2 (33.3) 0 9 (17.6) 11 (17.7) 0 (0)
Hypertension 0 1 (20.0) 9 (17.6) 10 (16.1) 1 (1.6)
Pruritus 1 (16.7) 0 7 (13.7) 8 (12.9) 0 (0)
Proteinuria 0 1 (20.0) 7 (13.7) 8 (12.9) 0 (0)
Serious AEs
320mg
(n¼ 6), n (%)
600mg
(n¼ 5), n (%)
800mg
(n¼ 51), n (%)
Total
(N¼ 62)
44% incidence,
any grade, n (%)
Disease progression 1 (16.7) 1 (20.0) 7 (13.7) 9 (14.5) —
Vomiting 0 1 (20.0) 3 (5.9) 4 (6.5) —
Dehydration 0 0 4 (7.8) 4 (6.5) —
Pyrexia 0 0 3 (5.9) 3 (4.8) —
Abbreviations: AE¼ adverse events; ALT¼ alanine transferase; AST¼ aspartate aminotransferase; CTC¼ common toxicity criteria.
Table 3 Effect of cetuximab on brivanib pharmacokinetics following
single 800mg doses of brivanib alaninate with cetuximab 400mgm–2 on
day 8 and without cetuximab 400mgm–2 on day 1
Treatment and
comparison
Cmax (ngml
– 1)
geometric
mean (CV)
AUC(INF)
(nghml – 1)
geometric
mean (CV)
Day 1: brivanib alaninate 3580.1 (42)a 45620.2 (44)b
Day 8: brivanib alaninate
plus cetuximab
3233.3 (50)c 42913.6 (58)d
Day 8: day 1 geometric
mean ratio point estimate (CI)
0.903 (0.803–1.016) 0.933 (0.838–1.039)
Abbreviations: AUC(INF)¼ area under the plasma concentration– time curve
extrapolated to infinity; Cmax¼maximum plasma concentration; CI¼ confidence
interval; CV¼ coefficient of variation. an¼ 50. bn¼ 48. cn¼ 49. dn¼ 4.
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therapy), patients with unknown K-Ras status and patients who
had received prior anti-EGFR therapies. Consistent with our
findings, results from a phase III study of cetuximab monotherapy
vs cetuximab plus irinotecan combination therapy in irinotecan-
refractory patients showed a median PFS of 1.5 months with
cetuximab monotherapy (Cunningham et al, 2004), and a separate
study of cetuximab monotherapy in patients who were refractory
or intolerant to both irinotecan and oxaliplatin by Jonker et al
(2007) reported a median PFS of 1.9 months, with an overall
survival of 6.1 months. Notably, the K-Ras wild-type subgroup in
the study by Jonker’s group had a response rate of 12.8% and
overall survival of 9.5 months (Karapetis et al, 2008). In contrast,
in the small subgroup of patients in the current study who had
K-Ras wild-type status and did not receive prior anti-EGFR-targeted
therapy, 6 of 11 patients had a partial response. However, it should be
noted that these K-Ras analyses were unplanned and, therefore,
limited. In a first-line setting, the combination of cetuximab with the
VEGF-A-binding monoclonal antibody bevacizumab and oxaliplatin-
based chemotherapy did not show a benefit for adding cetuximab in
patients with K-Ras wild-type tumours. In patients with K-Rasmutant
tumours, there was a detrimental effect (median PFS decreased from
12.5 to 8.1 months and overall survival decreased from 24.9 to 17.2
months) (Tol et al, 2009).
2[18F]Fluoro-2-deoxyglucose positron-emitting tomography is
increasingly becoming an integral part of multicentre trials for
tumour detection, staging and follow-up studies. In particular,
changes in SUV parameters over the course of treatment can serve
as an early surrogate marker for clinical benefit (Kelloff et al,
2005). The FDG-PET repeatability coefficients reported here
indicate that 95% of patients had an SUVmax per cent difference
in the two repeat baseline scans within 34% and 51%. Notably,
the lower repeatability coefficient value of 34% rather than the
25%, as suggested by European Organisation for Research and
Treatment of Cancer (EORTC) guidance, indicates a metabolic
response by SUVmax, while individual changes within 34% and
51% may not represent a metabolic response to treatment. The
metabolic response rate, as determined by FDG-PET, was similar
across all SUV parameters when assessed by the EORTC and lower
repeatability coefficient threshold. At the 800-mg dose, metabolic
response rate on day 15 (after 2 weekly doses of cetuximab and
1 week of continuous dosing of brivanib alaninate) was 53% by
EORTC criteria and 43% by repeatability threshold. In addition,
the metabolic response rate on day 56 was 39% by EORTC and
26% by repeatability threshold. Association of metabolic response
and clinical outcome was assessed by SUVmax, with results
suggesting that metabolic response at days 15 and 56, based on
the SUVmax parameter, may be associated with longer PFS in this
population. In addition, greater separation of the Kaplan–Meier
curves at day 56 than at day 15 may suggest that metabolic
response at day 56 is a better predictor of PFS, a hypothesis that
could be tested in future trials. Overall, these data support the
concept that metabolic response may represent a predictive
marker of clinical outcomes.
The promising efficacy observed in this study in patients with
advanced gastrointestinal cancer and the manageable toxicity profile
of brivanib justifies further study of brivanib in combination with
cetuximab. A prospective, randomised, phase III study of brivanib
alaninate plus cetuximab compared with placebo plus cetuximab in
patients with advanced colorectal cancer whose tumours are K-Ras
wild type and who have been previously treated with combination
chemotherapy but are treatment naive for EGFR-targeted therapy has
completed accrual February 2011 (the National Cancer Institute of
Canada trial, clinicaltrials.gov identifier: NCT00640471); this study
should help us better understand what additional benefit (if any)
brivanib adds in combination with cetuximab in patients with
advanced colorectal cancer.
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APPENDICES
Appendix A – Treatment
Dose modifications of brivanib alaninate and/or cetuximab were
made in response to AEs in individual patients. A minimum of
three patients were treated at each dose level. If a DLT was
observed in one of three patients at a given dose level,
an additional three patients were enrolled at that dose level
before further escalation was considered. At any dose level, up to
four additional patients could be enrolled (to a maximum of 10
patients per cohort) to obtain additional safety or efficacy data.
The MTD of the continuous daily dose schedule of brivanib
alaninate in combination with cetuximab was defined as the
highest dose of brivanib alaninate at which one-third or fewer of
the patients experienced a DLT. Once the MTD was determined, an
expansion cohort was to be evaluated at that dose; however, the
MTD was not formally reached and the expansion cohort was
opened at the predefined MDL based on the MTD (800mg)
reached in the phase I brivanib monotherapy study (CA182002)
(Jonker et al, 2010).
In the dose-expansion phase, only patients with histologic
verification of colorectal cancer were enrolled. In order to have 40
response-evaluable patients at the MDL, at least 50 patients with
advanced colorectal cancer were to be enrolled.
Appendix B – Analyses of cetuximab and brivanib
concentrations in serum and plasma
Serum cetuximab concentrations were measured by enzyme-linked
immunosorbent assay with colorimetric detection employing a
recombinant human EGFR full-length receptor adsorbed onto a
microtitre plate to capture cetuximab in 0.1% human serum. The
captured cetuximab was detected using a commercial rabbit-
antihuman IgGFC-HRP conjugate. The limits of quantitation
ranged from 1 to 32.0mgml– 1.
Brivanib concentrations were measured in glycinated plasma,
after solid-phase extraction by a liquid chromatography/
tandem mass spectrometry method using a stable-labelled internal
standard of brivanib ([13C3,15N2]BMS-540215). The internal
standard (50 ml at 100 ngml–1 for plasma) was added to 0.1ml of
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plasma sample and the samples buffered with ammonium formate
before loading onto solid-phase extraction plates (Waters
Corporation, Milford, MA, USA) conditioned with methanol and
an ammonium formate solution. After addition of the plasma
sample, the plates were washed with an ammonium formate
solution and acetonitrile/water. Samples were eluted from the
plates with methanol containing formic acid and evaporated to
dryness under nitrogen, and then reconstituted with an
acetonitrile/ammonium formate solution. The high-performance
liquid chromatography (HPLC) system consisted of a Shimadzu
HPLC pump (Shimadzu Corporation, Columbia, MD, USA), an
LEAP PAL Autosampler (LEAP Technologies, Carrboro, NC, USA)
and a Phenomenex column (Torrance, CA, USA) Luna Phenyl-
Hexyl, 5 mm 2.0 50mm2. The mobile phase flow rate was
0.3mlmin–1, and a gradient of two solvent systems, A and B,
was used for HPLC profiling. Solvent A consisted of 0.01M
ammonium formate solution in water. Solvent B consisted of
0.01M ammonium formate in acetonitrile/water. The HPLC system
was interfaced to a Sciex API 3000 mass spectrometer (Applied
Biosystems, Foster City, CA, USA) operated in the positive ion
electrospray ionisation mode. The total run time was B6.0min
and the retention time for brivanib and the internal standard were
B2.5min, with limits of quantitation ranging from 2 to
2000 ngm–1.
Appendix C – Efficacy analyses
Tumour measurements were obtained at screening (within 28 days
prior to the start of treatment), within 7 days of the start of every
second cycle of treatment (i.e. every 8 weeks), and at the end of
treatment. Efficacy end points included best overall clinical
response, PFS, ORR, disease control rate and prolonged disease
control (PDC, defined as a best overall response of complete
response, partial response or stable disease of at least 120 days)
rate, duration of response and duration of disease control. Patients
who never received treatment were not evaluable for response and
patients meeting the criteria for a complete or partial response had
confirmatory tumour measurements obtained between B4 and
6 weeks of initially demonstrating a response.
Appendix D – FDG-PET and K-Ras analyses
FDG-PET analysis 2[18F]fluoro-2-deoxyglucose positron-emit-
ting tomography analyses were performed as described previously
(Velasquez et al, 2009). In brief, FDG-PET scans were obtained
on two separate days within 14 days before day 1 (double baseline
scans) and then once on or around days 15 and 56 (prior to
cycle 3). Metabolic changes in tumour by FDG-PET were measured
by the SUV parameters SUVmax, SUVmean and SUVpeak, each
calculated as the sum of the parameter’s value across lesions.
Predictive biomarkers K-Ras mutation status was assessed by
sequencing of codons 12 and 13 from DNA isolated from paraffin-
embedded tumour tissue from colorectal cancer patients, as
reported previously (Karapetis et al, 2008).
Appendix E – Statistical analyses
Based on these two-stage approach, to determine whether a 15%
ORR was likely, 19 patients were accrued in the first stage. If no
responses were observed, it was concluded that the true response
rate was unlikely to beX15% and no more patients were enrolled
at this dose. If there was at least one response observed in the first
stage, 21 additional patients were enrolled at the MDL. With this
sample size, there was no45% chance of declaring that there was
no therapeutic effect when actually there was an effect. With a total
of 40 response-evaluable patients, the maximum width of the two-
sided 95% CI for ORR would be 25% when the ORR was in the
expected 15±12.5% range. To assess the effect of the combination
of brivanib alaninate and cetuximab at the MDL on the PK of
brivanib, point estimates and 90% CIs for the ratios of the
geometric means of brivanib Cmax AUC(INF) following adminis-
tration of brivanib alaninate with and without cetuximab were
constructed. The estimates were generated using a general linear
model on log(Cmax) and log(AUC(INF)) for patients treated at the
MDL, with treatment as a fixed effect and measurements within
each patient as repeated measurements. Point estimates and 90%
CIs for means and treatment differences on the log scale were
exponentiated to obtain estimates for Cmax and AUC(INF)
geometric means and ratios of geometric means on the original
scale. Summary statistics were tabulated for the brivanib PK
parameters Cmax and AUC(INF) by brivanib alaninate dose and
study day. For FDG-PET imaging biomarker analysis, repeatability
of SUV parameters was assessed by repeatability coefficients for
SUV parameters summarised by mean and maximum across
lesions. The mean (or mean per cent) baseline difference in each
SUV parameter was estimated by 95% CI for each parameter, and
the intrapatient coefficient of variation was calculated. Summary
statistics for SUVmean, SUVpeak and SUVmax (summed across
lesions) and changes from baseline were tabulated by brivanib
alaninate dose and FDG-PET scan visit (days 15 and 56). The
frequency of metabolic responders on days 15 and 56, based on the
EORTC criteria and on thresholds identified by the repeatability
analysis, was tabulated by brivanib alaninate dose for each
parameter. To explore associations between FDG-PET metabolic
changes by SUVmax and clinical outcome (PFS), point estimates,
and 95% CIs were calculated for median PFS for metabolic
responders and nonresponders using Kaplan–Meier methodology.
For K-Ras mutation analysis, Fisher’s exact test was used to assess
association between the mutation status and PDC status. In
addition, a logistic regression model was fit to model the
probability of disease control as a function of K-Ras mutation
status. A Cox proportional hazards model was used to assess the
relationship between PFS and K-Ras mutation status. Associations
were summarised in terms of point and interval estimates of odds
ratio (OR) and hazard ratios (HRs). The Kaplan–Meier product-
limit method was used to plot PFS by mutation status. K-Ras
mutation analyses were performed only in the 800-mg (MDL)
cohort, as 800mg was the dose selected for further clinical studies.
Appendix F – Results of FDG-PET and K-Ras analyses
FDG-PET Repeatability coefficients indicated that 95% of the
patients had an SUVmax per cent difference in the two repeat
baseline scans within –34% and 52% (Table 1a). Current EORTC
guidelines state that a metabolic response is defined as a reduction
of at least 25% in SUV parameters from baseline (Young et al,
1999). Based on the repeatability evaluation in this study,
metabolic response was determined using both the EORTC
threshold and the repeatability coefficient threshold of at least a
34% reduction in SUVmax. Metabolic responses at the MDL were
similar across all SUV parameters on each study day (Table 1b).
The metabolic response rate based on the EORTC guidelines was
53% on day 15 and 39% on day 56. However, the metabolic
response rate was somewhat lower when using the repeatability
thresholds, that is for SUVmax it was 43% on day 15 and 26% on
day 56. By either criterion (EORTC guidelines or repeatability
thresholds), fewer patients showed a metabolic response on day 56
compared with day 15, with 8 patients nonevaluable on day 15 and
18 patients nonevaluable on day 56. The frequency of metabolic
responses at the lower doses was similar, although this was based
on much smaller sample sizes. In the 800-mg cohort, the median
PFS among the metabolic responders using the repeatability
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coefficient threshold of at least a 34% reduction in SUVmax was
longer than median PFS among metabolic nonresponders on both
days 15 and 56, although the difference was less pronounced on
day 15 (Figure F1).
Predictive biomarkers Tumour K-Ras mutation analysis was
assessed in 45 patients in the brivanib alaninate 800mg cohort,
34 of whom had data on best overall response rate, and 30 of whom
had data on PDC. No patients with a K-Ras mutant tumour
achieved a radiographic partial or complete response. On the other
hand, 31.6% (6 out of 19) patients with a K-Ras wild-type tumour
had a partial response (Table F1a). In all, 11 of 15 patients with a
K-Ras mutant tumour (73.3%) had stable disease (X6 weeks),
while 8 of 19 (42.1%) patients with a K-Ras wild-type tumour had
stable disease (Table F1a); and 6 of the 11 (55%) patients who had
not received prior anti-EGFR therapy had a partial response
(Table F2b) and 9 (82%) had PDC (4120 days).
Prolonged disease control was observed in 25% (3 out of 12)
of patients with a K-Ras mutant tumour and in 66.7% (12 out of
18) of patients with a K-Ras wild-type tumour (uncorrected
P¼ 0.06 from Fisher’s exact test; P¼ 0.02 from logistic regression
model, OR [95% CI]¼ 0.17 [0.03, 0.79]). Median PFS was longer
in patients with K-Ras wild-type tumours than those with
K-Ras mutant tumours (218 vs 112 days, respectively; from the
Cox proportional hazards model, P¼ 0.01, HR [95% CI]¼ 2.82
[1.25, 6.36]).
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Figure F1 Kaplan–Meier plot of PFS by metabolic responder group FDG-PET repeatability threshold for metabolic changes at brivanib alaninate MTD
(800mg). (A) Day 15 and (B) day 56.
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Table F1 (a) FDG-PET reproducibility and other summary statistics for
baseline SUV parameters (N¼ 51). (b) Frequency of FDG-PET metabolic
responders in patients receiving the MDL (800mg) in combination with
cetuximab (N¼ 53)
(a)
N¼ 53 evaluable
SUV
parameter
Summary
across
lesions
Intrapatient
CV (%)
Mean per cent
difference point
estimate
(95% CI; %)a
95%
Repeatability
coefficients
(%)
SUVmax Average 15.9 1.9 (–3.3, 7.3) –33.6 50.1
Max 16.4 1.4 (–3.9, 7.0) –34.3 52.3
SUVmean Average 14.9 0.2 (–4.6, 5.3) –31.9 46.8
Max 15.4 1.2 (–3.9, 6.4) –32.8 48.9
SUVpeak Average 17.0 2.2 (–3.3, 8.1) –35.2 54.3
Max 17.3 2.0 (–3.6, 8.0) –35.7 55.6
(b)
Metabolic response criteria (N¼ 53 evaluable)
SUV
EORTC criteria
(425% reduction n, %)
RC criteria (SUV
reduction thresholdb n, %)
parameter Day 15 Day 56 Day 15 Day 56
SUVmax 27 (53) 20 (39) 22 (43) 13 (26)
SUVmean 27 (53) 19 (37) 21 (41) 17 (33)
SUVpeak 28 (55) 20 (39) 20 (39) 14 (27)
Abbreviations: CI¼ confidence interval; CV¼ coefficient of variation;
EORTC¼ European Organisation for Research and Treatment of Cancer; FDG-
PET¼ 2[18F]fluoro-2-deoxyglucose positron-emitting tomography; MDL¼maxi-
mum dose level; RC¼ repeatability coefficients; SUV¼ standardised uptake value.
aPercent difference of second from first scan based on geometric means from log-
transformed data. bSUVmax 434% reduction, SUVmean 432% reduction, SUVpeak
435% reduction.Percentages based on all patients with baseline SUV measurements.
Table F2 Frequency of tumour K-Ras mutation status by (a) best ORR
and (b) best ORR and prior anti-EGFR therapy (brivanib alaninate 800mg
dose group)
(a)
Partial
response
n (%)
Stable
diseasea
n (%)
Progressive
disease n (%)
Total,
n
K-Ras mutant 0 (0) 11 (73.3) 4 (26.7) 15
K-Ras wild type 6 (31.6) 8 (42.1) 5 (26.3) 19
(b)
K-Ras mutant 0 (0) 7 (63.6) 4 (36.4) 11
K-Ras wild type 6 (54.55) 3 (27.3) 2 (18.2) 11
Prior anti-EGFR therapy
K-Ras mutant 0 (0) 4 (100) 0 (0) 4
K-Ras wild type 0 (0) 5 (62.5) 3 (37.5) 5
Abbreviations: EGFR¼ epidermal growth factor receptor; ORR¼ overall response
rate. aX6 weeks.
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